Spain's Sylentis Looks to Move siRNA-Based Glaucoma Drug into Phase I This Year

Sylentis will perform the initial clinical trial on its own in Spain for logistical reasons, but expects to later test the topically administered drug in other countries, including the US, according to a company official.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories